Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques

Rachele M. Bochart1, Kathleen Busman-Sahay2, Stephen Bondoc2, David W. Morrow2, Alexandra M. Ortiz3, Christine M. Fennessey4, Miranda B. Fischer1, Oriene Shiel1, Tonya Swanson1, Christine M. Shriver-Munsch1, Hugh B. Cranko1, Kimberly M. Armantrout1, Aaron M. Barber-Axthelm1, Charlotte Langner3, Cassandra R. Moats1, Caralyn S. Labriola2, Rhonda MacAllister2, Michael K. Axthelm2, Jason M. Brenchley1, Brandon F. Keele2, Scott G. Hansen2, Jeremy V. Smedley1,2*

1 Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America, 2 Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America, 3 Barrier Immunity Section, Lab of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 4 AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America, 5 Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America

* smedley@ohsu.edu

Abstract

Here, we assessed the efficacy of a short-course multimodal therapy (enrofloxacin, azithromycin, fenbendazole, and paromomycin) to eliminate common macaque endemic pathogens (EPs) and evaluated its impact on gastrointestinal (GI) microbiota, mucosal integrity, and local and systemic inflammation in sixteen clinically healthy macaques. Treatment combined with expanded practices resulted in successful maintenance of rhesus macaques (RM) free of common EPs, with no evidence of overt microbiota diversity loss or dysbiosis and instead resulted in a more defined luminal microbiota across study subjects. Creation of a GI pathogen free (GPF) status resulted in improved colonic mucosal barrier function (histologically, reduced colonic MPO+, and reduced pan-bacterial 16s rRNA in the MLN), reduced local and systemic innate and adaptive inflammation with reduction of colonic Mx1 and pSTAT1, decreased intermediate (CD14+CD16+) and non-classical monocytes (CD14-CD16+), reduced populations of peripheral dendritic cells, Ki-67+ and CD38+ CD4+ T cells, Ki-67+IgG+, and Ki-67+IgD+ B cells indicating lower levels of background inflammation in the distal descending colon, draining mesenteric lymph nodes, and systemically in peripheral blood, spleen, and axillary lymph nodes. A more controlled rate of viral acquisition resulted when untreated and treated macaques were challenged by low dose intrarectal SIVmac239x, with an ~100 fold increase in dose required to infect 50% (AID50) of the animals receiving treatment compared to untreated controls. Reduction in and increased consistency of number of transmitted founder variants resulting from challenge seen in the
proof of concept study directly correlated with post-treatment GPF animal's improved barrier function and reduction of key target cell populations (Ki-67+ CD4+ T cells) at the site of viral acquisition in the follow up study. These data demonstrate that a therapeutic and operational strategy can successfully eliminate varying background levels of EPs and their associated aberrant immunomodulatory effects within a captive macaque cohort, leading to a more consistent, better defined and reproducible research model.

Author summary

Simian Immunodeficiency virus in macaques remains the most translational model for HIV. Macaques are also key models for other infectious diseases and colitis, where background colon health and inflammation could confound experimental results. To address these issues SPF breeding colonies were established to exclude specific viruses detrimental to mucosal and systemic health. To further improve macaque models, we established a gastrointestinal pathogen free (GPF) colony by administration of a multimodal therapeutic regimen for common endemic pathogens (EPs) and established expanded operational practices for continued exclusion. Through extensive longitudinal microbiota, parasitology, microbiology, and tissue sampling we demonstrated that our treatment and exclusion practices successfully eliminated common EPs, improved mucosal barriers, and reduced mucosal and systemic inflammation resulting in less inter-animal variation without overt evidence of microbiota disruption. Finally, compared to treatment-naïve controls, GPF animals challenged with SIV intrarectally demonstrated a more controlled and consistent rate of SIV acquisition, further indicating underlying EPs even at subclinical levels may cause deleterious variations between study subjects. Collectively the GPF macaque represents a model that eliminates a significant source of morbidity, reduces inter-animal variability, and thus has the potential to improve both animal welfare and research outcomes.

Introduction

Nonhuman primate (NHP) models of infectious disease, immunology, and inflammation are among the most predictive for human outcomes due to their close genetic and physiologic similarities. However, nosocomial viral, bacterial, and parasitic endemic pathogens (EPs) can have profound negative impacts on these research models due to immunologic and physiologic changes induced by these infections. In order to control for viral EPs in captive NHP colonies, institutions have established specific pathogen free (SPF) and expanded specific pathogen free (eSPF) rhesus macaque colonies, excluding four and nine viruses, respectively. SPF colonies exclude viruses such as *Macacine herpesvirus* 1, simian retrovirus type D, and simian immunodeficiency virus, all of which can have a significant impact on the macaque immune system and overall health, as well as present a zoonotic risk to workers[1]. Exclusion of these agents allows for a safer, more controlled, and well-defined biomedical research model [1]. However, these viruses represent only a small proportion of EPs which affect macaque health and introduce variability into research models.

Common bacterial and parasitic EPs within captive macaque populations include the gastrointestinal (GI) microbes *Campylobacter* spp. (*C. coli and C. jejuni*), *Shigella* spp., *Balantium* spp., *Entamoeba* spp., *Giardia* spp., *Strongyloides* spp., and *Trichuris* spp. [2]. These EPs have wide inter-institutional prevalence and can create significant mucosal inflammation comitant with GI barrier disruption [2,3]. As has been shown with dextran sulfate sodium
(DSS) treatment, disruptions of the mucosal barrier and the associated colitis can result in significant local and systemic inflammatory changes that mimic key pathologic features of simian immunodeficiency virus (SIV), inflammatory bowel disease, and ulcerative colitis [4,5]. Despite the importance of GI barrier integrity on local and systemic inflammation and the potential impact this can have on enhancing acquisition in low-dose SIV rectal transmission studies, these pathogens are often present at variable and sometimes high prevalence in rhesus macaques resulting in clinical and subclinical disease [6] at different times in different animals during the course of a study, which can serve as a confounding variable.

We first conducted a proof of concept study to evaluate the importance of eliminating common bacterial and parasitic endemic pathogens on SIV acquisition. There was an ~100 fold increase in intrarectal (IR) SIVmac239X dose required to infect 50% of the animals (AID_{50}) receiving treatment for common GI pathogens utilizing a short course multimodal therapeutic regimen (enrofloxacin, paromomycin, and fenbendazole), compared to untreated animals. We then sought to create and evaluate a “gastrointestinal pathogen free” (GPF) cohort of animals by utilizing a short course multimodal therapeutic regimen (enrofloxacin, paromomycin, fenbendazole, and azithromycin (added to target the elimination of Campylobacter spp.)) designed to eliminate common enteric EPs prior to study initiation. Towards that end, we assessed known pathogenic bacteria and parasites before and after treatment based on fecal culture and parasitology results, as well as the impacts of the treatment on the colonic microbiota. Furthermore, we evaluated inflammatory and mucosal barrier changes before and after achieving GPF status using histology, immunohistochemistry (IHC), pan-bacterial 16s rRNA RNAscope, and flow cytometry techniques within the GI-tract and GI-proximal sites (i.e., mesenteric lymph nodes and liver), as well as distal sites (i.e., spleen, blood, bronchoalveolar lavage, bone marrow, and axillary lymph nodes). Finally, we established expanded operational procedures to ensure maintenance of GPF status, and documented their efficacy maintaining this status through serial microbiological and parasitological examinations. We hypothesized that the administration of the multimodal treatment regimen and implementing refined exclusion practices would allow for maintenance of clinically healthy macaques free of common EPs, as well as improve the integrity of the gastrointestinal mucosa resulting in overt immunological and microbiota stabilization across study subjects, thus creating a more defined macaque research model.

Our study demonstrated that the short course multimodal treatment improved GI barrier function, reduced local and systemic inflammation in both the innate and adaptive immune systems, and reduced inter-animal variability. We also demonstrated that the regimen and associated practices were capable of creating and maintaining GPF status in rhesus macaques for over 6 months. Finally, the regimen did not result in the type of Proteobacterial bloom that would be of concern with antibiotic treatment, but resulted in a microbiome enriched for beneficial taxa including Clostridium clusters IV and XIVa, and free of pathogenic Shigella or Campylobacter spp. Together these findings indicate the potential to reduce the effects of bacterial and parasitic EPs on rhesus macaque models where variability in the timing and amount of associated clinical and subclinical disease, impacts to mucosal barrier function, and associated inflammation could significantly impact experimental outcomes.

Results

Proof of concept study evaluating acquisition of IR SIVmac239X and enumeration of transmitted/founder (T/F) variants in multimodal therapy treated and untreated rhesus macaques

IR challenge of untreated macaques with 1000 IU and 3000 IU resulted in infection of 1 out of 2 and 2 of 2 animals, respectively (Table 1). The number of detectable T/F variants for the 1000 IU
dose infected animal was 2 while the 3000 IU animals were infected with 6 and 8 variants. Based on both infection events and the number of T/F variants, we estimate an AID$_{50}$ of ~1000 IU for rectal challenge with this stock. Of six animals that received the multimodal treatment regimen (enrofloxacin, fenbendazole, and paromomycin) and maintained in a facility where all animals had been treated and testing demonstrated exclusion of common protozoan and metazoan parasites and *Shigella* spp. prior to challenge, none had detectable virus when identically dosed with 3000 IU. We then increased the dose to 30,000 IU which resulted in infection of 1 of 4 animals, with 2 T/F variants in the infected animal. We therefore increased the dose to 300,000 IU which resulted in infection of 6/6 animals with 1–4 T/F per animal as shown in Table 1. The animals that received the multimodal treatment regimen had an estimated AID$_{50}$ of ~100,000 IU, a 100-fold increase over the animals that did not receive the regimen. As the primary goal of this experiment was to determine the appropriate IR challenge dose to achieve a 100% rate of infection with consistent numbers of T/F variants, appropriate samples were not obtained to evaluate the EP status, nor the inflammatory, mucosal barrier or microbiome impacts of the multimodal therapy. We therefore conducted a follow-up study to evaluate the impacts on these key parameters in order to determine the changes that were associated with this drastic change in viral acquisition.

**Evaluation of the multimodal therapy regimen in rhesus macaques**

Sixteen male rhesus macaques were used to assess the levels of inflammation at gastrointestinal, draining and systemic sites, as well as colonic mucosal integrity following a short course
multimodal treatment aimed at establishing a GPF macaque model. Comprehensive sampling inclusive of peripheral blood, axillary and mesenteric lymph nodes (ALN and MLN), spleen, liver, distal descending colonic mucosa, and fecal samples were obtained prior to and after a short course multimodal treatment (enrofloxacin, azithromycin, paromomycin, and fenbendazole) regimen. Distal descending colonic mucosa samples were used to assess local inflammation and barrier integrity via IHC and flow cytometry at the site where a typical rectal SIV challenge would occur. Lymphoid tissues, liver, and blood were utilized to assess local GI-tract draining sites (liver and MLN) via flow cytometry and IHC, and systemic responses (blood, spleen, scopeless bronchoalveolar lavage (BAL), bone marrow (BM), and ALN) via flow cytometry. Fecal samples were utilized for parasitology, microbiology, and microbiome analyses; longitudinal microbiology and parasitic examinations continued to assess initial efficacy of treatment and the effectiveness of expanded EP exclusion practices to maintain this status.

Baseline microbiology cultures and parasitic examinations identified ten of sixteen animals with established EPs (Campylobacter coli (9/10), Shigella flexneri (1/10), and Trichurus spp. (6/10)) (Table 2). No animals developed significant clinical GI disease requiring treatment during the 6-month evaluation period after establishment of GPF status.

### Short course multimodal treatment regimen results in a consistent fecal microbiome across study animals

The short course multimodal treatment regimen employed drugs capable of eliminating the common GI bacterial and parasitic infections seen in rhesus macaques. Fenbendazole and paromomycin are effective against the common metazoan and protozoan parasites [7,8]. Enrofloxacin is highly efficacious against *Shigella* spp. [9], and azithromycin (added to the regimen for the ONPRC animals given the high prevalence of *Campylobacter* spp. in this colony) is similarly efficacious against *Campylobacter* spp. [10]. Doses and durations were based on veterinary experience with the drugs and agents being treated. The choice to use enrofloxacin, paromomycin, and fenbendazole concurrently was based on the bactericidal activity of these

| Table 2. Pre-treatment regimen fecal microbiology culture and parasitology examination results. |
|---------------------------------------------------------------|
| Animal | Microbiology | Parasitology |
|---|---|---|
| RM1 | N | - |
| RM2 | N | - |
| RM3 | N | - |
| RM4 | N | - |
| RM5 | N | - |
| RM6 | *Campylobacter coli* | - |
| RM7 | *Campylobacter coli* | *Trichurus* spp. |
| RM8 | *Campylobacter coli* | *Trichurus* spp. |
| RM9 | *Campylobacter coli* | *Trichurus* |
| RM10 | N | - |
| RM11 | N | - |
| RM12 | *Campylobacter coli* | *Trichurus* spp. |
| RM13 | *Campylobacter coli* | - |
| RM14 | *Campylobacter coli* | - |
| RM15 | *Shigella flexneri*, *Campylobacter coli* | *Trichurus* spp. |
| RM16 | *Campylobacter coli* | - |

(-) Negative, (N) Normal enteric flora

https://doi.org/10.1371/journal.ppat.1009565.t002

PLOS Pathogens | May 10, 2021 | 5/32
drugs and prior experience eliminating the common pathogens (except *Campylobacter* spp.) using this combined regimen, as well as it was utilized for the proof-of-concept study cohort. The decision to administer azithromycin (in an attempt to eliminate *Campylobacter* spp.) after completion of the other drug regimens was rooted in concerns about the potential of azithromycin to reduce the efficacy of the other agents in the regimen, as well as a concern for creating clinical dysbiosis by administering too many antibiotics at once. All animals had three rounds of negative culture and parasitology results prior to declaration of GPF status and commencement of post-treatment sampling.

After establishing an effective treatment to eliminate EPs, we then implemented enhanced exclusion practices in an attempt to maintain a long-term GPF colony (see Materials and Methods). This was done based on a previous study demonstrating that macaque fecal microbiome gradually reverts towards baseline following antibiotic and fecal microbial transplantation [11], and clinical experience with the spread of EPs within and between rooms in animal facilities. We therefore wanted to evaluate our methodology to prevent a relapse of EPs and their potential confounding immunological effects. To assess efficacy of our EP exclusion practices, five sets of longitudinal fecal samples were collected, and microbiological and parasitic examinations were performed. Diagnostic results revealed study animals successfully maintained in a GPF status for >6 months, indicating that the practices were successful in preventing exposure despite the presence of these agents in adjacent rooms in the facility (rhesus macaques in the adjacent room had the following EP prevalence: 23/27 (85%) *C. coli*, 5/27 (19%) *C. jejuni*, and 7/27 (26%) *S. flexneri*; no parasitology was performed on that cohort so the prevalence of parasites is unknown).

The fecal microbiome was compared pre- and post-treatment, by sequence analysis of DNA coding for the V4 hypervariable region of 16S ribosomal RNA, to determine if the short course multimodal therapeutic regimen resulted in less individual variation of phylogenetic taxa between animals. The predominant phylogenetic taxa were Firmicutes, Bacteroidetes, Spirochaetes, and Proteobacteria in all RM study cohorts (Fig 1B). Further t-test analysis of the relative abundance of Proteobacteria and family *Enterobacteriaceae* (bacterial populations associated with anti-microbial resistance) showed no evidence of enrichment with the studies’ multi-modal treatment regimen, but rather a decrease of the bacterial populations, although statistically insignificant (*p* = 0.144, *p* = 0.356). At the phylum and genus level, it is visually appreciable that the taxa distribution shows less individual variation following treatment (Fig 1B). Alpha diversity (measurement of species richness and/or diversity within a sample) did not significantly differ between pre- and post-treatment groups by quantitative and qualitative chao1 and Shannon diversity indices using a two-way paired t-test analysis (Fig 1C), although there is a considerable flattening of the post-treatment alpha diversity matrices curves, indicating that the treatment induces comparable diversity between the study subjects. Significantly increased beta diversity distance (measurement of differences between samples) and clustering of the pre- and post-treatment cohorts by the principal coordinate analysis of unweighted and weighted UniFrac metrics (permANOVA *p* = 0.001) (Fig 1D), further suggest that treatment created a more similar microbiome between study subjects, thereby reducing individuality.

Following treatment, the most common taxonomic shifts involved Clostridia genera, and significant relative abundance perturbance of genus *Treponema_2* were dually identified by DESeq 2 and dacomp taxonomic analyses (Fig 2). Specifically, when examining the relative abundance of the two specific bacterial pathogens that the treatment regimen aimed to reduce (*Campylobacter* spp., and *Shigella* spp.), we observed a reduction of the genus *Campylobacter* below the limit of detection by 16S sequencing, as well as the absence of *Campylobacter* and *Shigella* spp. by rectal culture. While our microbiome sequencing approach was unable to differentiate between *Shigella* from *Escherichia* (Fig 3), the absence of *Shigella* by rectal culture...
suggests that the remaining identified sequences likely belong to *Escherichia*. Collectively, these data indicate that our short course multimodal therapy successfully suppressed inter-animal phylogenetic differences, creating an increased similarity in fecal microbiota across study subjects.

**Short course multimodal treatment regimen improves gastrointestinal integrity and reduces gastrointestinal inflammation**

To evaluate distal descending colonic mucosal inflammation in study animals we utilized three IHC biomarkers (myeloperoxidase (MPO), phosphorylated signal transducer and activator of transcription 1 (pSTAT1), and type 1 IFN responsive gene myxovirus resistance protein 1 (Mx1)) as well as histologic scoring. Pre-treatment baseline mucosal samples of animals without identified EPs (*n* = 6), had significantly lower expression of MPO (*p = 0.031*) (Figs 4A and S1), a marker of neutrophil infiltration that directly correlates with reduced barrier integrity [4,12], in the colon lamina propria compared to animals with pre-existing EPs (*n* = 10). Importantly, following treatment and confirmation of GPF status, there were significant reductions in colonic neutrophil infiltration and mucosal inflammation (MPO *p = 0.0017*,...
Mx1 p = .0034, and pSTAT1 p = 0.0021) (Fig 4A, 4B, and 4C), which, combined with the reduction in histopathology score (p = 0.0004) (Fig 4D) indicating reduced inflammatory cell infiltration and improved mucosal and lamina propria architecture (S2 Fig), suggests

Fig 2. Multimodal therapy causes only a small subset of taxonomic genera to have microbiota community perturbances; enrichment of anti-microbial resistant Proteobacteria genera are not detected. (A) Dacomp and (B) DESeq2 analyses are used to assess for genera relative abundance differences for pre- and post-treatment timepoints for all study animals. Color distinguishes between different taxonomic phyla, shape/color distinguishes individual genera (see figure key), pre- and post-treatment timepoints are connected by a line for each genus. Genera classes jointly identified by the analyses are designated by (●). All genera differences represented by Dacomp and DESeq2 analyses are statistically significant (p-value < 0.004).

https://doi.org/10.1371/journal.ppat.1009565.g002

| Genus Shigella | Genus Campylobacter |
|----------------|---------------------|
| Relative Frequency (Bacteria) | Relative Frequency (Bacteria) |
| Pre | Post | Pre | Post |
| p=0.366 | | p=0.144 |

Fig 3. Multimodal therapy showed some bacterial community perturbances of Shigella and Campylobacter, although statistically insignifcant, animals did remain culture free of pathogenic species post-treatment. (A) The relative abundance for genus Shigella comparing pre- and post-treatment regimen for study animals, assessed by paired t-test analysis. (B) The relative abundance of genus Campylobacter comparing pre- and post-treatment regimen for study animals, assessed by paired t-test analysis.

https://doi.org/10.1371/journal.ppat.1009565.g003
elimination of EPs and/or the enrichment of beneficial taxa result in restoration of the GI-tract epithelial barrier and attenuates inflammation. Additionally, the inter-animal variability, as assessed by variance from the mean, was significantly reduced in both groups post-treatment (MPO p = 0.04, Mx1 p = .0038, and pSTAT1 p = 0.026). CD4+ T lymphocyte and CD68/CD163+ tissue macrophage populations remained unaltered, although the inter-animal variability of CD4+ T cells was significantly reduced after treatment (p = 0.0187) (S1 Fig).

Short course multimodal treatment regimen results in decreased immune cell activation and proliferation in the GI-tract

We utilized 9-color and 14-color multiparameter flow cytometric immune surveillance panels to assess changes in innate and adaptive immune populations pre- and post-treatment. Changes in innate immune cell frequencies (specifically monocytes, pDC, and mDC) indicate host responses to foreign antigens and inflammation within tissues [13]. Furthermore, increased expression of CD169 on monocytes can indicate immune activation in response to pathogens, especially in the context of lentiviruses and adenoviruses. Following innate responses to pathogens, adaptive immune responses can be characterized by activation (increased CD38 expression)[14] and proliferation (increased Ki67 expression)[15] in T cell memory subsets.

Following treatment and confirmation of GPF status, there were no significant changes in CD4+ T cell memory populations in the distal descending colon (Fig 5A). However, a significant reduction in proliferation (Ki-67+) of naïve (p<0.0001), T_{CM} (p<0.0001), T_{TEM} (p = 0.0006), and T_{EM} (p = 0.0058) CD4+ T cell subsets was exhibited (Fig 5B). Additionally, the inter-animal variability in Ki-67+ CD4+ T cells was significantly reduced post-treatment (p = 0.0038). Finally, establishment of GPF status resulted in a decrease in CD38+ T_{CM} (p = 0.0325), T_{TEM} (p = 0.0077) and T_{EM} (p = 0.0211) CD4+ T cells (Fig 5C). Reductions of non-classical CD14^{low}CD16+ monocytes (p = 0.0165) and pDCs (p<0.0001) were also observed within the descending colon (Fig 5D). In agreement with previous reports [2], our results demonstrate background EPs cause local immune activation and inflammation with reduced mucosal integrity and barrier breaches. Regardless of initial EP status on rectal culture/parasitology, these data suggest that our short course multimodal therapy resulted in a more consistent mucosal immunological environment across study subjects, improved barrier integrity, and reduced local inflammation.

Inflammation and immune activation at GI-tract draining sites are reduced following short course multimodal therapy

Mesenteric lymph nodes are the most proximal site to receive lymph draining from the GI-tract, while the liver is the first site to encounter GI-tract venous blood via the portal vein. These sites are potentially exposed to higher concentrations of leukocytes, inflammatory mediators, microbes and microbial products from the GI-tract when barrier breaches and inflammation are present. To evaluate the impact of treatment leading to GPF status on inflammation and immune activation we performed quantitative IHC (MPO and Mx1) and
flow cytometry as described above with the addition of B cell phenotypes (memory, activation, and proliferation) which were possible due to the larger yield of lymphocytes from the MLN. Additionally, changes in CD21 expression [16] and IgM/IgG levels [17] were assessed and can be indicative of B cell maturation or isotype switching in response to ongoing antigen stimuli. Following treatment, there was a significant reduction in liver Mx1 expression (p = .0088) (Fig 6), but no significant changes within MLN. However, there was a significant reduction of intermediate CD14+CD16+ (p = 0.0030) and non-classical CD14-CD16+ (p < 0.0001) monocytes from MLN following treatment (Fig 7A). Treatment leading to GPF status also resulted in a significant reduction of activated Ki-67+, naive (p<0.0001), T_{CM} (p = 0.0011), T_{TrEM} (p = 0.0015), and a trend toward reduction of activated T_{EM} (p = 0.0574) CD4+ T lymphocytes in MLN (Fig 7B), as well as a decrease in CD38+ T_{CM} (p = 0.0007) and T_{TrEM} (p = 0.0008) CD4+ T cells in MLN. Furthermore, treatment leading to GPF status also resulted in a significant reduction of Ki-67+ naive B cell proliferation (p = 0.0033) and a trend for reduced Ki-67 expression among IgD+ and IgD- memory B cells (Fig 7C).

While neutrophil infiltration (MPO staining) in the GI lamina propria is a strong surrogate marker for local epithelial damage, we sought to directly quantify translocated microbiota in the draining lymphatic chain by assessing pan-bacterial 16s rRNA in the MLN (Fig 8), specifically focusing on the subset of animals displaying GI tract neutrophil infiltration or inflammation in any biopsy specimen prior to treatment leading to GPF status. Importantly, the number of translocated bacteria (as measured by the percent area of the MLN occupied by bacterial 16s rRNA) was significantly (p = 0.0156) reduced in animals following treatment to generate GPF status (Fig 8). In combination with our gastrointestinal data, reduction in hepatic Mx1, activated macrophages, and activation/proliferation of CD4+ T and B cells as well as reduced microbial translocation to MLNs following treatment leading to GPF status suggests this strategy leads to decreased exposure to pro-inflammatory signals (leukocytes, inflammatory mediators, microbes and microbial antigens) at these GI-tract draining sites due to elimination of EPs, resulting in improved integrity of the mucosal barrier.

Elimination of EPs following short course multimodal therapy normalizes systemic inflammation and immune activation

Finally, we evaluated systemic inflammation and adaptive immune activation pre- and post-treatment in peripheral blood, spleen, BAL, BM, and ALN samples using flow cytometric panels described above. Treatment leading to development of GPF status resulted in reductions of monocyte and pDC cell populations (Fig 9A), specifically, significantly lower proportions of intermediate CD14+CD16+ monocytes in peripheral blood (p = 0.0343), spleen (p = 0.0008) and ALN (p<0.0001), and a reduction of non-classical CD14-CD16+ monocytes in spleen (p<0.0001) and ALN (p<0.0001). As expected, peripheral blood also contained lower
proportions of circulating CD169+ monocytes (p = 0.0019) as well as an influx of splenic CD169+ monocytes (p = 0.0022). Furthermore, post-treatment GPF status resulted in lower levels of pDCs in peripheral blood (p = 0.0457), ALN (p = 0.0387) and spleen (p = 0.0073), likely due to reduced antigen exposure and trafficking to these sites. No significant differences between pre- and post-treatment were observed in BAL or bone marrow.

After treatment leading to GPF status, a reduction of naïve B cell proliferation (Ki-67 expression) was evident in peripheral blood (p = 0.0004), ALN (p < 0.0001) and spleen (p < 0.0001) (Fig 9B). Reduced levels of Ki-67 expression were also present in IgD+ memory B cells in ALN (p < 0.0001) and spleen (p = 0.0017), as well as on IgD- memory B cells in peripheral blood (p = 0.0001), ALN (p = 0.0077) and spleen (p = 0.0008) tissues. Furthermore, all B
Fig 7. Inflammation and immune activation at GI-tract draining sites are reduced following short course multimodal therapy. Flow cytometric analysis was performed on B cells, CD4+ T cells, DCs, and MOs derived from mesenteric lymphoid tissue, before and after multimodal treatment. Subsets were summed for overall responses with the figure showing the mean (+ SEM) of these overall responses both pre- and post-treatment. A reduction in both CD14+ CD16+ and CD14- CD16+ monocytes was observed, as well as a decreased SEM for CD169+ expression by all
cell IgG responses (naïve p<0.0001; IgD- memory p = 0.0072; IgD+ memory p<0.0001) decreased in peripheral blood, and a similar trend occurred in IgD+ memory B cells in ALN (p<0.0001) and spleen (p<0.0001) tissues, as well as in naïve splenic B cells (p<0.0001) after treatment (Fig 9C).

Evaluation of adaptive immune cell proliferation (Ki-67 expression) revealed a significant post-treatment reduction in the proportion of activated Ki-67+ CD4+ T lymphocytes in peripheral blood (naïve p<0.0001, T_CM p = 0.0156, T_EM p = 0.0041), and spleen (naïve p<0.0001, T_CM p = 0.0007, T_EM p = 0.0006), as well as decreased expression of Ki-67+ naïve CD4+ T lymphocytes in ALN (p<0.0001) (Fig 10A). We also observed changes in T cell activation with a decrease in CD38+ T_CM CD4+ T cells in blood (p = 0.0259), ALN (p<0.0001) and spleen (p = 0.0001); in T_TRM CD4+ T cells in blood (p = 0.0311), ALN (p<0.0001) and spleen (p<0.0001) and in T_EM CD4+ T cells in blood (p = 0.0039) (Fig 10B).

Altogether, our data indicate reduced activation of local, draining, and systemic monocytes, dendritic cells, CD4+ T cells and B cells following treatment, which, combined with the histology, MPO and pan-bacterial 16s rRNA staining, indicates that these changes were due to decreased microbial antigen presentation as a result of improved integrity of the mucosal barrier.

Discussion

We have demonstrated that creation and maintenance of gastrointestinal pathogen free (GPF) rhesus macaques for >6 months is possible using a short course multimodal therapy followed by enhanced animal care practices resulting in significantly reduced levels and inter-animal variability of inflammation at local, draining, and systemic sites, as well as improved colonic mucosal barrier function. With the goal of obtaining more stable baseline microbiome data, animals chosen for this interventional study had not received antibiotics for at least 2 months nor had evidence of diarrhea for at least 6 months prior to collection of baseline samples. As the vast majority of animals screened did not meet these selection criteria, the animals presented in this work represent a cohort of animals that is healthier than average at the ONPRC and likely minimized the potential to demonstrate a positive impact of the therapy. Despite this, we demonstrated that GPF status resulted in improved mucosal barrier function as evidenced by histopathology and reduced levels of MPO+ neutrophils in the distal descending colon by IHC, as well as reduced pan-bacterial 16s rRNA in GI tract draining MLNs. We also demonstrated reduced intermediate (CD14+CD16+) and non-classical monocytes (CD14-CD16+), reduced populations of peripheral dendritic cells, Ki-67+ and CD38+ CD4+ T cells, Ki-67+IgG+, and Ki-67+IgD+ B cells. These findings indicate lower levels of background inflammation in the distal descending colon, draining mesenteric lymph node, and systemically in peripheral blood, spleen, and axillary lymph node.

We also demonstrated reduced inflammation in the distal descending colon (Mx1, pSTAT1) and liver (Mx1) via IHC. The inter-animal variability of inflammatory and immune activation markers was reduced resulting in a more consistent baseline between research animals upon which to evaluate the impact of experimental manipulations. More consistent outcomes in NHP studies could possibly reduce the number of animals required to achieve statistical significance in models of immunology, inflammation, and infectious diseases. The importance of these changes for SIV macaque models was demonstrated by a proof of concept.
Fig 8. Microbial translocation to draining lymph nodes is reduced following short course multimodal therapy. RNAscope was performed on a subset of animals in which colonic or peripheral inflammation was observed via other markers (e.g. MPO, Mx1, pSTAT1, etc.), to quantify translocated bacteria within the inferior MLN using pan-reactive 16s rRNA probes. After treatment to induce GPF status, a marked decrease in 16s rRNA was observed in MLN, consistent with restoration of the GI epithelial barrier.

https://doi.org/10.1371/journal.ppat.1009565.g008
study where the IR SIVmac239X AID50 was 100-fold higher in animals that had received a multimodal treatment regimen similar to what was used to generate the GPF animals. Unfortunately, we did not assess EPs or levels of inflammation or disruptions in the mucosal barrier in these proof of concept animals. Other animals from the same shipment/source as the proof-of-concept animals had positive results for *Shigella* spp., *Strongyloides* spp., *Balantidium* spp. and *Entamoeba* spp., prior to treatment and post-treatment, for the cohort that received the short course multimodal therapy, the proof of concept animals were housed in a facility which excluded *Shigella* spp., and parasitic EPs (*Entamoeba* spp., *Balantidium* spp., *Strongyloides* spp., and *Trichuris* spp.), and were longitudinally confirmed free of EPs through serial diagnostic sampling. However, in our follow-up study the changes were largely consistent regardless of detected background EP status prior to treatment. One limitation of the follow up study is that we performed a single set of assessments (rectal culture, fecal parasitology, and microbiome assessment) prior to initiation of the short course multimodal therapy. We deemed it likely that any EPs that were significantly influencing the local, draining and systemic inflammatory state would be present at high enough levels to be detected on a single exam. In a majority of study animals, the impact of pre-study cleanup was more significant in animals with demonstrable EPs. However, the benefit of cleanup when comparing inter-animal

Fig 9. Elimination of EPs following short course multimodal therapy normalized systemic inflammation and immune activation in innate myeloid and B cells. Flow cytometric analysis was performed on B cells, DCs, and MOs derived from whole blood, spleen and axillary lymphoid (ALN), before and after multimodal treatment. Subsets were summed for overall responses with the figure showing the mean (+ SEM) of these overall responses both pre- and post-treatment. Reduced SEM was observed in most tissues with significant decreases in total CD16+ populations in spleen and ALN (A) along with significant reductions of pDCs in those tissues. Increased splenic CD169+ on myeloid cells was also observed (A, panel 4). A reduction in B cell expressions of the proliferation marker Ki67 (B) and IgG (C) in all memory subsets was observed in whole blood, spleen and ALN, showing reduced immune activity in those tissues after therapeutic treatment. Immune cell subsets were defined as described in Figs 5 and 7.
variability was clearly present, irrespective of the background EP status. Thus, it is strongly suggestive there were either additional EPs not detected by the single pre-treatment assessment or that additional bacterial/parasitic EPs that are not recognized by our standard assessments were present. For example, *Escherichia coli* spp. which have been reported to have ~25% prevalence in some macaque colonies, can cause opportunistic GI disease [2], and require specialized assays to detect the presence of virulence genes that differentiate them from normal flora.

Fig 10. Elimination of EPs following short course multimodal therapy normalized systemic inflammation and immune activation in CD4+ T cells. Flow cytometric analysis was performed on CD4+ T cells derived from whole blood, spleen and axillary lymphoid (ALN) tissues, before and after multimodal treatment. Subsets were summed for overall responses with the figure showing the mean (+ SEM) of these overall responses for both pre- and post-treatment. Reduction in proliferation (Ki67) was observed in all tissues (A), especially in central and transitional memory subsets, as well as in whole blood and splenic effector memory populations. Decreased activation (CD38) was also observed in the central and transitional memory subsets in all three tissues (B) as well as in the effector memory subset in whole blood. Immune cell subsets were defined as described in Fig 5.

https://doi.org/10.1371/journal.ppat.1009565.g010
Microbiota play an influential role on host health, with beneficial bacterial communities (i.e. probiotics (Lactobacillus spp.)) having gastro-protectant properties [19] and enrichment of pathobiont bacterial populations correlating with local (e.g., Crohn’s disease) and systemic (e.g., Alzheimer’s, rheumatoid arthritis) diseases [20–22]. One of the aims of this study was to determine if using a short course multimodal therapeutic regimen (paromomycin, fenbendazole, azithromycin, and enrofloxacin) would control for differences between the gastrointestinal microbiota of study subjects. In contrast to previous literature that utilized a variety of antibiotics (paromomycin, clindamycin, cephalaxin, vancomycin +/- or enrofloxacin) in immune-competent or compromised macaques [23–25], our study’s therapeutic regimen did not result in a loss of microbiota diversity, which is the most common indicator of intestinal dysbiosis [26], however our study did not include untreated temporal controls for comparison. Manuzak et al demonstrated that antibiotic (enrofloxacin, paromomycin, clindamycin, or cephalaxin) related microbiota loss was transient and recovered by day 28 post-administration [25]. Therefore, our data may not have captured this transient loss due to sampling at 6 weeks post-treatment. Similar to previous reports, our beta diversity pCoA results demonstrate that treatment increased study subject clustering and a definitive difference was shown between individual baseline and post-treatment time points, representing a decrease in study subject inter-individual variability and demonstrating microbial community perturbation between study time points [23–25]. The macaques in this study showed no phylogenetic phyla differences with treatment, with the predominant phyla being Firmicutes, Bacteroidetes, Spirochaetes, and Proteobacteria across study subjects. Phylogenetic bacterial community shifts were present at the genus level. Dacom and DEseq2 analyses conjointly identify perturbances of species, Treponema_2, and the order Clostridiales (gram negative obligate anaerobes) as the most common genus population showing disturbances. Therefore, this study’s short course multimodal therapeutic regimen reduced inter-individuality between microbiota of study subjects with only modest levels of genera perturbation. With the use of a multimodal antibiotic and parasitic treatment, we did not see higher proportions of Enterobacteriaceae which is linked to multi-drug resistance and can have pro-inflammatory properties [23]. Consistent with our results, previous literature have found paromomycin and azithromycin did not result in Proteobacteria enrichment rather a phylum reduction [25,27] likely explaining why expansion of Proteobacteria was not seen with our multimodal treatment. Importantly, through longitudinal diagnostic testing and expanded procedure practices we were able to achieve long-term exclusion of EPs, establishing a GPF colony. To our knowledge, this is the first demonstration that rhesus macaques can be maintained free of Campylobacter spp. for an extended period of time. The microbiota overall shows less individuality and appears to control for overt bacterial community outliers within study subjects. This, in combination with the beneficial effects of controlling for underlying immune activation and inflammation, as well as the added benefit of occupational protection from common zoonotic EPs, makes for an ideal macaque for a number of research models. Antibiotic resistance could become an issue, however several factors help to mitigate this risk; 1) to date we have not detected any of the pathogenic bacteria we are attempting to eliminate after completion of the therapeutic regimen, 2) though an in-depth assessment has not been performed, we have not observed increased rates of antibiotic resistance in other bacterial populations in treated animals when clinical samples are taken for procedures such as wound care, though the number of samples to date in treated cohorts is quite small, and 3) as these models are terminal, and given the practices employed, there is little risk of transmitting resistant bacteria to other animals/cohorts if they were to occur. Further studies are needed to evaluate how quickly the microbiome stabilizes after the regimen ends.
Rhesus macaques are commonly used as models for human immunodeficiency virus (HIV) and there are established SPF4 and SPF9 breeding colonies to meet the need for Indian origin rhesus macaques for these studies. Studies have demonstrated that for HIV as well as pathogenic SIV infections, the GI-tract is the major site for pathogenesis despite the route of acquisition. During the SIV/HIV acute phase, the gut mucosa and lamina propria undergo immunological and cellular disruptions, increased mucosal permeability, damage, and microbial translocation, which perpetuates chronic immune activation and disease progression [12,28–30]. Pathogenesis can be impacted by background levels of colitis as evidenced in elite controller macaques and African Green Monkeys (AGM) where administration of DSS resulted in increased viral loads and increased viral loads with loss of mucosal CD4+ T cells, respectively [4].

Disruptions of mucosal barriers and mucosal inflammation have also been shown to promote HIV/SIV acquisition. A prior macaque study [31] showed that levels of Ki-67+ effector memory CD4+ T cells correlated with increased acquisition and higher peak viremia in an intrarectal SIV challenge model. Importantly, in this study we demonstrate that treatment resulted in significantly reduced Ki-67+ effector memory CD4+ T cells, as well as reduced inter-animal variability in GPF animals. It is well documented that bacterial, parasitic and viral sexually transmitted infections (STIs) promote HIV acquisition in humans when present at the site of mucosal exposure (oral, vaginal, and/or rectal) due to disruptions in barrier integrity and increases in activated CD4+ T cells [32]. Other ulcerative colitis-inducing agents have additionally been shown to correlate with HIV status [33]. It has been shown for instance that men who have sex with men with HIV are at greater risk for Entamoeba histolytica infection, but the data might also support the conclusion that barrier breaches and inflammation associated with E. histolytica, which were well-documented by colonoscopy, augmented activated CD4+ T cell populations and increased the risk of rectal HIV acquisition [34]. In fact, it was recently shown that an experimental animal’s colony of origin had a significant impact on a SHIV macaque model in which animals from two different source colonies, presumably with different prevalence of EPs, had a per challenge acquisition rate of 47% versus 21% when identically challenged [35].

In conclusion, we have demonstrated the ability to create and maintain macaques free of common bacterial and parasitic GI pathogens using the gold standard assays (rectal culture and fecal flotation/wet mount parasite exams) for these agents. These GPF macaques have improved GI mucosal barrier function, which leads to a reduction in local, draining, and systemic inflammation and reduced inter-animal variability across a host of parameters. This reduced variability could produce more consistent outcomes both between cohorts within an institution as well as between institutions, leading to improved rigor and reproducibility in key preclinical macaque models. There is also the potential to achieve statistically significant results using fewer animals which can both serve to reduce animals utilized as called for in the 3R’s [36] and reduce costs in these models. Finally, as these agents can lead to clinical disease that can be severe and debilitating, preventing them also serves as a refinement per the 3Rs, meets the expectations of the Guide for the Care and use of Laboratory animals (ref preventive medicine section) [37], and augments animal welfare.

**Materials and methods**

**Ethics statement**

All nonhuman primates were maintained at AALAC-accredited facilities, and animal research was performed in accordance to institutional policies and approved by the Institutional Animal Care and Use Committee.
Study animals, treatment regimen description, and timeline of tissue collection procedures.

Proof of concept study assessing the impact of the multimodal treatment regimen on acquisition of SIVmac239X

A total of 18 healthy male Indian-origin rhesus macaques between 3 and 6 years of age were used in accordance to the policies of the Institutional Animal Care and Use Committee at the National Cancer Institute (NCI), an AAALAC-accredited institution, which abides by the USDA Animal Welfare Regulations [38] and the Guide for the Care and Use of Laboratory Animals [37]. Animals were socially-housed during the study in accordance with the IACUC protocol and facility practices. All enrolled macaques were research naive, had not received antibiotics for at least 2 months, and were SPF (serologically negative for simian T-lymphotropic virus-1, SIV, simian type D retrovirus, and Macacine herpes 1) prior to the start of the study. Animals were genotyped for common MHC Class I alleles using allele-specific PCR as previously described [39] Mamu-A*01, -B*08 and -B*17 animals were excluded from this study. Throughout the study, all animals were uniformly fed Purina LabDiet 5045 (Purina Mills International, St. Louis, MO), daily nutritional enrichment items (grains, fruits, or vegetables), ad libitum access to water, and were not exposed to additional pre-, pro-, or anti-biotic therapeutics after receiving the study-related treatment regimen. Animals assigned to the treatment regimen were administered courses of enrofloxacin (10 mg/kg intramuscularly (IM) every 24 hours for 10 days), paromomycin (25 mg/kg orally (PO) every 12 hours for 10 days), and fenbendazole (50 mg/kg PO every 24 hours for 5 days) administered simultaneously as was done in the follow up study, and a cage change occurred on day 8 or 9 to ensure no pathogens would be reintroduced from the cage. No further exclusion practices were required in this facility as all animals were treated with this regimen prior to being admitted to the facility, and testing showed the facility to be free of Shigella spp., and parasitic EPs. Using transfection derived SIVmac239X [40], 18 macaques were challenged intrarectally (IR) with varying doses of SIVmac239X in 3 x 1 ml volume of RPMI. Animals without pre-treatment (n = 4) were challenged with either 1x10^3 or 3x10^3 infectious units (IU) as determined by TZM-bl assay (reference no. 8129; NIH AIDS Research and Reference Reagent Program). Animals treated with the multimodal therapy (n = 16) were challenged intrarectally with either 3x10^3, 3x10^4, or 3x10^5 IU in the same 3 x 1 ml volume. IR SIVmac239X challenge was performed as previously described [41]. Blood draws were obtained twice weekly post-challenge and infection status determined both by a positive quantitative real-time PCR outcome as previously described [42] and by single genome sequencing of plasma as described below.

Assessment of the multimodal treatment regimen

An additional 16 healthy male Indian-origin rhesus macaques between 3 and 6 years of age were used in accordance to the policies of the Institutional Animal Care and Use Committee at the Oregon National Primate Research Center (ONPRC), an AAALAC-accredited institution, which abides by the USDA Animal Welfare Regulations [38] and the Guide for the Care and Use of Laboratory Animals [37]. All animals were captive-born at ONPRC and inhabited socially-housed indoor/outdoor enclosures before their transfer to indoor standardized housing prior to study start and socially-housed during the study in accordance with the IACUC protocol and facility practices. All enrolled macaques were research naive, had not received antibiotics for at least 2 months, had no GI disease requiring antibiotics for at least 6 months, and were SPF (serologically negative for simian T-lymphotropic virus-1, SIV, simian type D retrovirus, and Macacine herpes 1) prior to the start of the study. Animals were genotyped for common MHC Class I alleles using allele-specific PCR as previously described [24,39]. Mamu-
A’01, -B’08 and -B’17 animals were excluded from this study. Throughout the study, all animals were uniformly fed Purina LabDiet 5000 (Purina Mills International, St. Louis, MO), daily nutritional enrichment items (grains, fruits, or vegetables), ad libitum access to water, and were not exposed to additional pre-, pro-, or anti-biotic therapeutics after receiving the study-related treatment regimen. Prior to treatment all animals were assessed for background EP status by rectal culture (intrarectal sample (BBL CultureSwab)), fecal parasitology (free catch collection), and by fecal microbiota analysis (via sterile rectal loop, placed directly into a collection conical and placed on dry ice until stored at -80 degrees Celsius prior to processing). Animals assigned to the treatment regimen were administered courses of enrofloxacin (10 mg/kg IM every 24 hours for 10 days), paromomycin (25 mg/kg PO every 12 hours for 10 days), fenbendazole (50 mg/kg PO every 24 hours for 5 days), and azithromycin (40 mg/kg PO for first day followed by 20 mg/kg PO once a day for 4 days). The enrofloxacin and paromomycin were started together on day 1, fenbendazole was added on day 6, and a cage change occurred on day 8 or 9 to ensure no pathogens would be reintroduced from the cage. The azithromycin began the day after completion of the other 3 drugs (i.e. day 11). Three animals received an additional round of fenbendazole 6 weeks prior to the post-treatment sampling due to a *Trichuris* spp. positive parasitology result in two of the animals, and concern for exposure of a socially housed-partner. Consistent with the definition of SPF and eSPF where animals are only considered SPF/eSPF after they are removed from any exposure to non-SPF animals and have at least two rounds of negative tests post last potential exposure [1], animals were only considered GPF once they had been treated with the multimodal treatment regimen, tested to ensure negative status, and were no longer exposed to any non-GPF animals post treatment. Again, as with SPF/eSPF the level of certainty of GPF status increases with additional time and testing post last potential exposure. All animals had three rounds of negative culture and parasitology results prior to declaration of GPF status and post-treatment sampling. All enrolled study animals had baseline samples of spleen, mesenteric lymph nodes (MLN), and liver by a minimally invasive laparoscopic surgery [43], scopeless bronchoalveolar lavage (BAL) [44], microbiome fecal collection, axillary lymph node (ALN), bone marrow, and distal descending colonic mucosal pinch biopsies taken prior to administration of the treatment. These samplings were repeated 6 weeks post-administration of the last dose of the additional round of fenbendazole. Additionally, animals were followed by culture and parasitology for 6 months following the last round of fenbendazole to ensure maintenance of GPF status.

### Description of practices to maintain gastrointestinal pathogen free (GPF) status

We established GPF animal biosecurity practices (based in large part on our successful eSPF practices) to exclude common EPs in macaque research colonies. GPF animal rooms were positioned in a location to limit work traffic and designated as first entry rooms to promote optimal compliance for facility workflow and further prevent EP fomite contamination. The area in front of the animal rooms was partitioned off by a taped line to create a physical barrier and serve as a multipurpose work area which functioned as GPF PPE, husbandry and research (i.e., food, equipment) storage, and staff/animal workspace. Upon entering the demarcated GPF workspace, all staff don new/clean GPF-designated PPE, including new Tyvek suits, boot covers, gloves, face shields, masks, and hair bonnets. All consumables used in the study were new or clean prior to animal distribution and stored separately from the rest of the animal colony. All non-consumable enrichment, research, husbandry, and diagnostic equipment were new or disinfected prior to animal introduction or contact. Cages and husbandry equipment were transferred directly from the clean cage wash to the animal rooms with casters disinfected
as they crossed into the tape-designated clean area. Surgical equipment and procedural rooms were disinfected prior to study-related use and GPF animals underwent planned procedures prior to other colony animals. Once animals were assigned to a GPF study, their electronic record alerted veterinary staff to consult the principal investigator prior to prescribing pre-, pro-, or anti-biotic medications to prevent study-confounding variables. To reduce physiological stress, animals were acclimated to designated GPF rooms 4 weeks prior to study start.

**Flow cytometry assays**

Peripheral blood, bone marrow, BAL, spleen, ALN, MLN, liver and descending colon pinch biopsy samples were obtained as described above and were processed then stained for flow cytometric analysis. Peripheral blood was collected in an ACD BD Vacutainer (BD, 364606). ALN, MLN, spleen, BAL, and bone marrow were collected in R10 media (RPMI-1640 with 10% sterile filtered Newborn Calf Serum, 1% penicillin-streptomycin, 1% L-glutamine, 1% sodium pyruvate, and 50 nM/mL of 2-Mercaptoethanol) at biopsy. ALN, MLN and spleen were processed using a pestle and screen for CD-1 (Sigma-Aldrich, S1020-5EA) in a tissue culture dish. Processed tissues were strained through a 40 μm filter into a 50 mL conical, centrifuged at 700 rcf for 10 minutes, and resuspended in R10 before obtaining the cell yield using a Horiba ABX Pentra 60 C+ hematology analyzer. Bone marrow was processed similarly to the above tissue, with omitting the CD-1 screen.

Liver and descending colon biopsy tissues were processed using a gentleMACS Octo Disso- ciator with Heaters (Miltenyi Biotech). The tissue samples were incubated in 12 mL of R3 media (same as R10 but with 3% sterile filtered Newborn Calf Serum) supplemented with 300μg/mL DNase-I (Roche Applied Science, REF# 10104159001) and 150 μg/mL collagenase (Sigma, C9722), aliquoted into a gentleMACS C tube (Miltenyi Biotech, Auburn, CA). The dissociator was programmed to agitate two sets of clockwise/counter-clockwise at 300 rpm for 20 sec and at 50 rpm for 40 min following by another round of clockwise-counter-clockwise 20 sec agitation at 37˚C. The isolated cells were strained through a 70 μm filter, centrifuged at 700 rcf for 10 minutes, and resuspended in R10 media before obtaining the cell yield using a Horiba ABX Pentra 60 C+ hematology analyzer.

Flow cytometric assays were performed on an LSR II Becton Dickinson instrument. Data were analyzed using the FlowJo software program (version 9.9.6; Ashland, OR: Becton, Dickinson and Company; 2020). Each assay used 1x10⁶ lymphocytes per biopsy tissue and/or 100 μL of peripheral blood.

T cells were defined by CD3 positivity and small lymphocyte light scatter. CD3+ T cells were further defined by CD4 and CD8 positivity. Memory and naïve T cell subsets were delineated based on CD28, CCR7, and CD95 expression patterns on gated CD4⁺ or CD8⁺ T cells. Each subset was defined as: Naïve: CD28⁺ CD95⁻ CCR7⁻, Central Memory (T_CML): CD28⁺ CD95⁺ CCR7⁺, Transitional Memory (T_TRM): CD28⁺ CD95⁺ CCR7⁻, and Effector Memory (T_EM): CD28⁻ CD95⁺ CCR7⁻. B cells were defined by CD20 positivity and small lymphocyte light scatter. Memory and naïve B cell subsets were defined by CD27 positivity (memory) with additional subsets defined by IgD expression (IgD⁺ and IgD⁻). Monocyte subsets were defined by expression of CD14 and CD16 (classical: CD14⁺ CD16⁻, intermediate: CD14⁺ CD16⁺ and non-classical: CD14⁻ CD16⁺), while myeloid (mDC) and plasmacytoid (pDC) dendritic cells were defined by the lack of CD14 and differing expressions of CD11c and CD123, respectively.

**Antibodies**

The following fluorophore-conjugated antibodies were used in this study: from BD Biosciences: anti-CD4 (L200; BUV395), anti-CD8a (SK-1; BUV737 and BV510), anti-CD28
(CD28.2; BV510), streptavidin (BV605), anti-CD21 (B-ly4; BV711), anti-IgG (G18-145; BV786), anti-Ki67 (B56; FITC), anti-IgM (G20-127; PE-CF594), anti-CD123 (7G3; PerCP Cy5.5) and anti-CD3 (SP34-2; Alexa Fluor 700); from BioLegend: anti-CCR7 (G043H7; Biotin), anti-CD27 (M-T271; BV421), anti-CD16 (3G8; Pacific Blue), anti-CD14 (M5E2; FITC), anti-CD169 (7–239; PE), anti-HLA-DR (L243; PE-Dazzle), anti-CD95 (DX2; PE-Cy7), anti-CD11c (3.9; APC), and anti-CD20 (2H7, APC/Fire 750); From Novus: anti-CD38 (AT1;APC); From SouthernBiotech: anti-IgD (polyclonal; PE).

**T cell gating hierarchy**

Whole blood and tissue-derived lymphocytes were stained using fluorophore conjugated monoclonal antibodies and analysis was performed using a LSR II Becton Dickinson instrument. The resulting list mode multi-parameter data files were analyzed using the FlowJo software program (version 9.9.6; Ashland, OR: Becton, Dickinson and Company; 2020) with the hierarchy shown here. CD3⁺ small lymphocytes were selected and divided into CD4⁺ and CD8⁺ T cell subsets, then defined as memory and naïve T cell subset populations based on CD28 and CD95 expression patterns. Memory subsets were then further differentiated by their expressions of CD28 and CCR7. Naïve (CD28⁺ CD95⁻), central memory (CD28⁺ CD95⁺ CCR7⁺), transitional memory (CD28⁺ CD95⁺ CCR7⁻), and effector memory (CD28⁻ CD95⁺ CCR7⁻) T cells were then analyzed for subsets manifesting upregulation of the markers for activation (CD38 and proliferation (Ki67) (S3 Fig).

**B cell gating hierarchy**

Whole blood and tissue-derived lymphocytes were stained and analyzed using the software described above. CD20⁺ small lymphocytes were selected and divided into memory (IgD⁺/⁻ CD27⁺) and naïve (IgD⁺ CD27⁻) B cell subsets. The subsets were further analyzed for upregulation of activation marker CD38, proliferation marker Ki67, complement receptor CD21, as well as surface expression of immunoglobulins G and M (S4 Fig).

**Dendritic cell, monocyte/macrophage hierarchy**

Whole blood and tissue-derived lymphocytes were stained and analyzed using the software described above. CD3⁻ CD20⁻ HLA-DR⁺ lymphocytes were selected and divided into monocyte/macrophage populations based on CD14 and CD16 expression. Dendritic cells were further defined by their lack of CD14 and CD16 as well as their expression of CD11c (myeloid DC) and CD123 (plasmacytoid DC). Upregulation of the activation marker CD169 was also measured on all HLA-DR⁺ lymphocytes (S5 Fig).

**Immunohistochemistry and quantitative image analysis**

Tissues were fixed in freshly prepared 4% paraformaldehyde for 24 hours, transferred to 70% ethanol, and paraffin embedded within 5 days. Slides (5 μm sections) were deparaffinized in xylene and rehydrated through a series of graded ethanol to distilled water. Heat induced epitope retrieval (HIER) was performed with the antigen retrieval buffers citrate (Thermo, pH 6.0, AP-9003-500; for MPO), citraconic anhydride (0.01% containing 0.05% Tween-20; for Mx1), or Tris-HCl (0.01M, pH 8.6; for pSTAT1) in a Biocare NxGen Decloaking Chamber at 110°C for 15 minutes, cooled for 20 minutes, then rinsed twice in ddH2O and 1x TBS with 0.05% Tween-20 (TBS-T). Slides were incubated with blocking buffer (TBS-T with 0.25% casein) for 30 minutes at room temperature, rinsed with TBS-T, and incubated at room temperature with antibodies against MPO (Dako; Cat. No. A0398), Mx1 (EMD Millipore Cat. No.
MABF938; clone M143/CL143), or pSTAT1 (Cell Signaling; Cat. No. 9167L), which were diluted in blocking buffer. Endogenous peroxidases were blocked with 1.5% H2O2 in TBS-T for 10 minutes. Slides were then incubated with Rabbit Polink-1 HRP (GBI Labs; Cat. No. D13-110; for MPO), Mouse Polink-2 HRP (GBI Labs; Cat. No. D37-110; for Mx1), or Rabbit Polink-2 HRP (GBI Labs; Cat. No. D39-110; for pSTAT1). Slides were developed using Impact DAB (3,3′-diaminobenzidine; Vector Laboratories), washed in ddH2O, counterstained with hematoxylin, mounted in Permount (Fisher Scientific), and scanned at 20x magnification on an Aperio AT2 (Leica Biosystems).

**Histopathologic examination and scoring**

Colonic pinch biopsies were fixed in 4% paraformaldehyde for 24 hours and transferred to 80% ethanol at 4°C for 24–72 hours until processed and embedded in paraffin. Paraffin sections were cut at 5 μm and serially dehydrated and de-paraffined before routine staining with hematoxylin and eosin. Tissue sections were blindly assessed by standard light microscopy by two pathologists using Leica DFC495 microscopes. There was an average of six biopsy per section, and each slide contained two sections. Five random, non-consecutive 40x fields selected to contain both mucosa and submucosa were evaluated (using the scoring schema below). Scores from the five fields were averaged, and any additional comments added.

**Inflammatory cell infiltrate**

| Location | Type | Severity (% infiltrate per 40x field) |
|----------|------|-------------------------------------|
| 1 = Mucosa only | 1 = Lymphoplasmacytic +/- minimal eosinophilic | 1 = Minimal (<10%) |
| 2 = Mucosa +/- segmental submucosa or +/- segmental crypt epithelium | 2 = Lymphoplasmacytic + minimal histiocytic +/- mild to moderate eosinophilic | 2 = Mild (10–25%, infiltrating, no expansion) |
| 3 = Mucosa + moderate crypt epithelium + submucosa | 3 = Lymphoplasmacytic + mild histiocytic +/- mild to moderate neutrophilic and eosinophilic | 3 = Moderate (25–50%, dense infiltrates +/- mild expansion) |
| 4 = Mucosa + crypt epithelium + crypt abscesses +/- submucosa | 4 = Predominantly neutrophilic and/or histiocytic + lymphoplasmacytic | 4 = Marked (>51%, dense infiltrates + expansion of lamina propria) |

**Epithelial/lamina propria changes**

| Hyperplasia | Epithelial necrosis | Superficial extracellular/intrahistiocytic cellular debris |
|-------------|--------------------|---------------------------------------------------------|
| 0 = None | 0 = none | |
| 1 = Minimal hyperplasia | 1 = Mild epithelial degeneration (apoptosis) | 1 = Minimal |
| 2 = Mild hyperplasia, mild goblet cell loss, +/- rare mitoses in upper 1/3rd of crypts | 2 = Focal erosion +/- epithelial degeneration | 2 = Mild |
| 3 = Moderate hyperplasia, moderate elongation of crypts, moderate mitoses in upper third of crypt epithelium +/- moderate goblet cell loss | 3 = Moderate erosion | 3 = Moderate (diffusely superficial +/- mild expansion) |
| 4 = Marked hyperplasia, many mitoses in upper third of crypts, +/- marked goblet cell loss, +/- crypt atypia | 4 = Marked erosion +/- focal ulceration | 4 = Marked (expansion of lamina propria, increased depth) |

https://doi.org/10.1371/journal.ppat.1009565.t003
16S rRNA mesenteric lymph node RNAscope in situ hybridization and analysis

RNAscope in situ hybridization was performed as previously described using pan-reactive 16s rRNA probes (ACD Cat. No. 414461). In brief, after slides were deparaffinized in xylene and rehydrated through a series of graded ethanol to distilled water, retrieval was performed for 30 min in ACD P2 retrieval buffer (ACD Cat. No. 322000) at 95–98˚C, followed by treatment with protease III (ACD Cat. No. 322337) diluted 1:10 in PBS for 20 min at 40˚C. Slides were then incubated with 3% H2O2 in PBS for 10 min at room temperature. Prior to hybridization, probes stocks were centrifuged at 13,000 rpm using a microcentrifuge for 10 min, then diluted 1:2 in probe diluent (ACD Cat. No. 300041) to reduce probe aggregation tissue artifacts. Slides were developed using the RNAscope 2.5 HD Detection Reagents-RED (ACD Cat. No.322360), counterstained with CAT-hematoxylin (Biocare), mounted in Permount (Fisher Scientific), and scanned at 40x magnification on an Aperio AT2 (Leica Biosystems). Quantitative image analysis was performed using HALO software (v3.0.311.405; Indica Labs) on two inferior MLNs sections from each analyzed animal, pre-treatment and post-treatment. The ISH v.3.4.3 module was used to detect 16s rRNA and is presented as a proportion of total LN tissue (area/μm²). Manual curation was performed on each sample to ensure the annotations were accurate and to correct false positives.

16S isolation and analysis

16S rDNA was isolated from stool and sequenced on the MiSeq Illumina platform as previously described [45]. Raw Illumina FASTQ files were first demultiplexed using a custom Python script. Returned paired-end FASTQ reads were filtered and processed using the DADA2 package (v1.14.1) in RStudio (v1.1.463) to infer Amplicon Sequence Variants (ASVs) at a 99% identity threshold using the Silva database (v132). Before quality trimming 5,608,297 reads were included in 32 samples with an average of 175,259 reads per sample. Reads were trimmed to 200bp and filtered to exclude sequences with degenerate bases (N), more than 2 expected errors (maxEE), or chimerism. DADA2 quality trimming resulted in 2,333,726 reads for all the samples with an average of 72,929 reads per sample. Three samples with less than 1000 reads and 3 resultant unpaired samples were omitted from further analysis. ASVs identified as non-bacteria, mitochondria (Rickettsiales Mitochondria), and Cyanobacteria were removed from further consideration as they were present generally at less than 3% prevalence or with no Family diversity. Fully analyzed 16S miSeq data (n = 26) are deposited in the NCBI Sequence Read Archive (SRA) under project number PRJNA633758.

Nucleic acid extraction and quantification/single genome sequencing

Viral RNA from blood was sequenced using a combination real-time, SGA and Sanger sequencing described previously [40]. Briefly, a 300-bp portion of the integrase gene surrounding the mutated site was amplified and sequenced by a limiting-dilution PCR where only a single genome is amplified (SGA) per reaction [46]. vRNA was extracted with the QIAamp vRNA minikit (Qiagen) and then reverse transcribed into cDNA with SuperScript III reverse transcriptase according to manufacturer’s recommendations (Invitrogen). The cDNA was mixed with 1× reverse transcription (RT) buffer, 0.5 mM each deoxynucleoside triphosphate, 5 mM dithiothreitol, 2 U/ml RNaseOUT (RNase inhibitor), 10 U/ml Superscript III reverse transcriptase, and 0.25 mM antisense primer SIVmacIntR1 (5’-AAG CAA GGG AAA TAA GTG CTA TGC AGT AA-3’) and incubated at 50˚C for 60 min and at 55˚C for 60 min, heat inactivated at 70˚C for 15 min, and then treated with 1 U of RNase H at 37˚C for 20 min. PCR was
then performed with a reaction mixture of 1× PCR buffer, 2 mM MgCl2, 0.2 mM each deoxy-
nucleoside triphosphate, 0.2 μM each primer, and 0.025 U/μl Platinum Taq polymerase (Invi-
trogen) in a 10 -μl volume. Real-time PCR was performed with sense primer SIVmacIntF1 (5’-
GAA GGG GAG GAA TAG GGG ATA TG-3’) and antisense primer SIVmacIntR3 (5’-CAC
CTC TCT AGC CTC TCC GTG ATC C-3’) under the following conditions: 1 cycle of 94˚C
for 2 min and 40 cycles of 94˚C for 15 sec, 55˚C for 30 sec, 60˚C for 1.5 min, and 72˚C for 30 s.
Template-positive reactions were determined by real-time PCR with SIVIntP 5’-TCC CTA
CCT TTA AGA TGA CTG CTC CTT CCC CT-3’ with 6-carboxyfluorescein and ZEN/Iowa
Black Hole Quencher (Integrated DNA Technologies) and directly sequenced with SIVma-
cIntR3 by Sanger sequencing using BigDye Terminator technology (Life Technologies).

**Statistical analyses**

Sequencing abundance and diversity were assessed using the Phyloseq package (v1.30.0) in
RStudio. Alpha diversity was quantified as Observed richness and Shannon diversity, with sig-
nificance assessed by paired, two-way t-test. Beta-diversity was assessed by unweighted and
weighted UniFrac, with statistical significance assessed by PERMANOVA. The empirical iden-
tification of differentially abundant bacterial taxa was determined using the DESeq2 (v1.26.0)
and dacomp (v1.22) packages in RStudio. Reported abundance significance results from paired
testing and incorporates package-specific p-value adjustments for multiple-comparisons.
DESeq2 was run utilizing the likelihood ratio test function and dacomp using the Wilcoxon
function. No data that met minimum threshold requirements as outlined in these Materials
and Methods were excluded.

For statistical comparisons from flow cytometric data, unpaired t-tests followed by Mann-
Whitney test was performed using GraphPad Prism version 8.0.0 (macOS, GraphPad Soft-
ware, San Diego, California USA, www.graphpad.com). For statistical comparisons from IHC
and histology data, either Wilcoxon matched-pairs signed rank tests (pre-treatment/post-treat-
ment) or Mann-Whitney tests (intergroup comparisons) were performed again using Graph-
Pad Prism version 8.0.0. Inter-animal variability was determined using the Lavene’s test
performed using QI Macros Statistical Software for Excel (KnowWare International Inc. Den-
ver, Colorado USA, qimacros.com).

**Supporting information**

S1 Fig. Inflammation is reduced, and T cell infiltration normalized, in the descending
colon following treatment. (A) Representative images of formaldehyde-fixed, paraffin-
embedded descending colon biopsies demonstrate the dramatically reduced neutrophil
recruitment (MPO) observed following the clean-up regimen. (B) IHC quantification of CD4
+ T cells and macrophages (CD68/CD163) was performed using HALO, which demonstrated
markedly reduced inter-animal variance (P = 0.0187) assessed by Wilcoxon signed-rank test.
(C) Despite a negligible change in overall IHC staining (CD4+ and CD68/CD168) between
pre and post-treatment groups (scale bars = 100μm).
(PDF)

S2 Fig. IHC and histological measures of colonic inflammation significantly reduced fol-
lowing treatment. Representative images of Mx1, pSTAT1, and H&E-stained sections of
colon exhibiting the pre-and post-treatment changes observed with treatment designed to cre-
te GPF status. Pre-treatment sections (left-hand column) had higher staining for (A) Mx1,
(B) pSTAT1, as well as (C) increased severity of inflammation and spread to the submucosa
(asterisk), increased epithelial hyperplasia and necrosis (arrowhead), and more superficial
macrophages with intracytoplasmic cellular debris. Some high-scoring sections had crypt abscesses (arrow). Post-treatment, minimal (A) Mx1 and (B) pSTAT1 were observed, and (C) low-scoring sections were relatively quiescent with normal submucosal gut-associated lymphoid tissue (dotted line) and low numbers of lamina propria lymphocytes. (PDF)

S3 Fig. T cell gated hierarchy. Whole blood and tissue-derived lymphocytes were stained using fluorophore conjugated monoclonal antibodies and analysis was performed using a LSR II Becton Dickinson instrument. The resulting list mode multi-parameter data files were analyzed using the FlowJo software program (version 9.9.6; Ashland, OR: Becton, Dickinson and Company; 2020) with the hierarchy shown here. CD3⁺ small lymphocytes were selected and divided into CD4⁺ and CD8⁺ T cell subsets, then defined as memory and naïve T cell subset populations based on CD28 and CD95 expression patterns. Memory subsets were then further differentiated by their expressions of CD28 and CCR7. Naïve (CD28⁺ CD95⁻), central memory (CD28⁺ CD95⁺ CCR7⁻), transitional memory (CD28⁺ CD95⁺ CCR7⁺), and effector memory (CD28⁻ CD95⁻ CCR7⁻) T cells were then analyzed for subsets manifesting upregulation of the markers for activation (CD38) and proliferation (Ki67). (PDF)

S4 Fig. B cell gated hierarchy. Whole blood and tissue-derived lymphocytes were stained and analyzed using the software described above. CD20⁺ small lymphocytes were selected and divided into memory (IgD⁻/⁺ CD27⁺) and naïve (IgD⁺ CD27⁻) B cell subsets. The subsets were further analyzed for upregulation of activation marker CD38, proliferation marker Ki67, complement receptor CD21, as well as surface expression of immunoglobulins G and M. (PDF)

S5 Fig. Dendritic cell, monocyte/macrophage hierarchy. Whole blood and tissue-derived lymphocytes were stained and analyzed using the software described above. CD3⁻ CD20⁻ HLA-DR⁺ lymphocytes were selected and divided into monocyte populations based on CD14 and CD16 expression. Dendritic cells were further defined by their lack of CD14 and CD16 as well as their expression of CD11c (myeloid DC) and CD123 (plasmacytoid DC). Upregulation of the marker CD169 was also measured on all HLA-DR⁺ lymphocytes. (PDF)

Acknowledgments

We would like to thank Nancy L. Haigwood, Director of the ONPRC, Kimberly Cook for her assistance with figure formatting, as well as the Behavioral Services, Clinical Medicine, Surgical Services, and Operations units within the Division of Comparative Medicine at the ONPRC for their continued support throughout this study.

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Author Contributions

Conceptualization: Christine M. Fennessey, Miranda B. Fischer, Kimberly M. Armantrout, Aaron M. Barber-Axthelm, Cassandra R. Moats, Rhonda MacAllister, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Data curation: Kathleen Busman-Sahay, Stephen Bondoc, David W. Morrow, Alexandra M. Ortiz, Caralyn S. Labriola, Michael K. Axthelm, Jeremy V. Smedley.
Formal analysis: Rachele M. Bochart, Kathleen Busman-Sahay, Stephen Bondoc, David W. Morrow, Alexandra M. Ortiz, Christine M. Fennessey, Oriene Shiel, Hugh B. Crank, Charlotte Langner, Cassandra R. Moats, Caralyn S. Labriola, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Funding acquisition: Rhonda MacAllister, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Investigation: Kathleen Busman-Sahay, David W. Morrow, Alexandra M. Ortiz, Christine M. Fennessey, Miranda B. Fischer, Oriene Shiel, Tonya Swanson, Christine M. Shriver-Munsch, Hugh B. Crank, Kimberly M. Armantrout, Aaron M. Barber-Axthelm, Cassandra R. Moats, Caralyn S. Labriola, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Methodology: Rachele M. Bochart, Kathleen Busman-Sahay, Stephen Bondoc, David W. Morrow, Alexandra M. Ortiz, Christine M. Fennessey, Miranda B. Fischer, Oriene Shiel, Tonya Swanson, Christine M. Shriver-Munsch, Hugh B. Crank, Kimberly M. Armantrout, Aaron M. Barber-Axthelm, Cassandra R. Moats, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Project administration: Rachele M. Bochart, Kathleen Busman-Sahay, David W. Morrow, Miranda B. Fischer, Tonya Swanson, Christine M. Shriver-Munsch, Hugh B. Crank, Kimberly M. Armantrout, Aaron M. Barber-Axthelm, Cassandra R. Moats, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Resources: Miranda B. Fischer, Kimberly M. Armantrout, Cassandra R. Moats, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Software: Hugh B. Crank.

Supervision: Rachele M. Bochart, Kathleen Busman-Sahay, Christine M. Fennessey, Miranda B. Fischer, Oriene Shiel, Tonya Swanson, Christine M. Shriver-Munsch, Kimberly M. Armantrout, Aaron M. Barber-Axthelm, Cassandra R. Moats, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Validation: Charlotte Langner, Michael K. Axthelm.

Visualization: Stephen Bondoc, Jacob D. Estes.

Writing – original draft: Rachele M. Bochart, Kathleen Busman-Sahay, David W. Morrow, Alexandra M. Ortiz, Christine M. Fennessey, Caralyn S. Labriola, Michael K. Axthelm, Jason M. Brenchley, Brandon F. Keele, Jacob D. Estes, Scott G. Hansen, Jeremy V. Smedley.

Writing – review & editing: Rachele M. Bochart, Kathleen Busman-Sahay, Stephen Bondoc, David W. Morrow, Alexandra M. Ortiz, Christine M. Fennessey, Miranda B. Fischer, Oriene Shiel, Tonya Swanson, Christine M. Shriver-Munsch, Hugh B. Crank, Kimberly M. Armantrout, Aaron M. Barber-Axthelm, Charlotte Langner, Cassandra R. Moats, Caralyn S. Labriola, Rhonda MacAllister.
References

1. Yee JL, Vanderford TH, Didier ES, Gray S, Lewis A, Roberts J, et al. Specific pathogen free macaque colonies: a review of principles and recent advances for viral testing and colony management. Journal of Medical Primatology. 2016; 45(2):55–78. https://doi.org/10.1111/jmip.2016.45.issue-2 PMID: 26932456

2. Sestak K, Merritt CK, Borda J, Saylor E, Schwamberger SR, Cogswell F, et al. Infectious Agent and Immune Response Characteristics of Chronic Enterocolitis in Captive Rhesus Macaques. Infection and Immunity. 2003; 71(7):4079–86. https://doi.org/10.1128/iai.71.7.4079-4086.2003 PMID: 12819098

3. Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK, et al. An altered intestinal mucosal mucobiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunology, 2014; 7(4):983–94. https://doi.org/10.1038/mi.2013.116 PMID: 23999150

4. Hao XP, Lucero CM, Turksey B, Bernardo ML, Morcock DR, Deleage C, et al. Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection. Nature Communications. 2015; 6(1):8020. https://doi.org/10.1039/ncomms9020 PMID: 26282376

5. McQueen P, Busman-Sahay K, Rieder F, Noel-Romas L, McCorriston S, Westmancott G, et al. Intestinal proteomic analysis of a novel non-human primate model of experimental colitis reveals signatures of mitochondrial and metabolic dysfunction. Mucosal Immunology. 2019; 12(6):1327–35. https://doi.org/10.1038/s41385-019-0200-2 PMID: 31481749

6. Sassesseville VG, Mansfield KG. Overview of known non-human primate pathogens with potential to affect colonies used for toxicity testing. Journal of Immunotoxicology. 2010; 7(2):79–92. https://doi.org/10.3109/15476910903213521 PMID: 19909217

7. Reichard MV, Thomas JE, Chavez-Suarez M, Cullin CO, White GL, Weydsh EC, et al. Pilot Study to Assess the Efficacy of Ivermectin and Fenbendazole for Treating Captive-Born Olive Baboons (Papio anubis) Coinfected with Strongyloides stuebneri and Trichuris vulpis. J Am Assoc Lab Anim Sci. 2017; 56(1):52–6. PMID: 28905715

8. Nakamura S, Itagaki I, Nakagawa T, Kawamoto I, Asano T, Arakawa D, et al. Paromomycin sulfate is an effective treatment for balantidiasis in captive cynomolgus monkeys. Exp Anim. 2019; 68(3):285–92. https://doi.org/10.1538/expanim.18-0133 PMID: 30814394

9. Klein H, Hasselshewt D, Handt L, Kastello M. A pharmacokinetic study of enrofloxacin and its active metabolite ciprofloxacin after oral and intramuscular dosing of enrofloxacin in rhesus monkeys (Macaca mulatta). J Med Primatol. 2008; 37(4):177–83. https://doi.org/10.1111/j.1600-0684.2008.00280.x PMID: 18384536

10. Crushell E, Harty S, Sharf F, Bourke B. Enteric campylobacter: purging its secrets? Pediatr Res. 2004; 55(1):3–12. https://doi.org/10.1203/01.PDR.0000099794.06260.71 PMID: 14605259

11. Hensley-McBain T, Zevin AS, Manuzak J, Smith E, Miller C, et al. Effects of Fecal Microbial Transplantation on Microbiome and Immunity in Simian Immunodeficiency Virus-Infected Macaques. J Virol. 2016; 90(10):4981–9. https://doi.org/10.1128/JVI.00099-16 PMID: 26937040

12. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogen free simian immunodeficiency virus infections. PLoS Pathog. 2010; 6(8):e1001052. https://doi.org/10.1371/journal.ppat.1001052 PMID: 20808901

13. Grabowska J, Lopez-Venegas MA, Affandi AJ, den Haan JMM. CD169+ Macrophages Capture and Set of Mature T Cells with Reduced Proliferation but Improved Potential to Produce Cytokines. Cell Immunol. 2014; 310(9):150–9. https://doi.org/10.1538/cellimm.2014.01166.00 PMID: 25304654

14. Sandovol-Montes C, Santos-Argumedo L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. Journal of Leukocyte Biology. 2005; 77(4):513–21. https://doi.org/10.1189/jlb.0404262 PMID: 15618297

15. Drach J, Gattringer C, Glassl H, Schwarting R, Stein H, Huber H. Simultaneous flow cytometric analysis of surface markers and nuclear Ki-67 antigen in leukemia and lymphoma. Cytometry. 1989; 10(6):743–9. https://doi.org/10.1002/cyto.990100612 PMID: 2684579

16. Das A, Xu H, Wang X, You CL, Veazey RS, Pahar B. Double-positive CD21+CD27+ B cells are highly proliferating memory cells and their distribution differs in mucosal and peripheral tissues. PLoS One. 2011; 6(1):e16524. https://doi.org/10.1371/journal.pone.0016524 PMID: 21304587

17. Stavnezer J, Jeroen E, Guikema J, Schrader CE. Mechanism and Regulation of Class Switch Recombination. Annual Review of Immunology. 2008; 26(1):261–92. https://doi.org/10.1146/annurev.immunol.26.021607.090248 PMID: 18370922

18. Palaniappan RU, Zhang Y, Chiu D, Torres A, Debroy C, Whittam TS, et al. Differentiation of Escherichia coli pathotypes by oligonucleotide spotted array. J Clin Microbiol. 2006; 44(4):1495–501. https://doi.org/10.1128/JCM.44.4.1495-1501.2006 PMID: 16597882
19. Vujkovic-Cvijin I, Swainson LA, Chu SN, Ortiz AM, Santee CA, Petriello A, et al. Gut-Resident Lactobacillus Abundance Associates with IDO1 Inhibition and Th17 Dynamics in SIV-Infected Macaques. Cell Rep. 2015; 13(8):1589–97. https://doi.org/10.1016/j.celrep.2015.10.026 PMID: 26586432

20. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, et al. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019; 8(3). https://doi.org/10.3390/pathogens8030126 PMID: 31412603

21. Horta-Baas G, Romero-Figueroa MDS, Montiel-Jarquin AJ, Pizano-Zárate ML, García-Mena J, Ramirez-Durán N. Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis. J Immunol Res. 2017; 2017:4835189. https://doi.org/10.1155/2017/4835189 PMID: 28948174

22. Kowalski K, Mulak A. Brain-Gut-Microbiota Axis in Alzheimer’s Disease. J Neurogastroenterol Motil. 2019; 25(1):48–60. https://doi.org/10.5056/jnm.18087 PMID: 30646745

23. Zevin AS, Hensley-McBain T, Miller C, Smith E, Langevin S, Klett NR. Antibiotic treatment disrupts bacterial communities in the colon and rectum of simian immunodeficiency virus-infected macaques. FEMS Microbiol Lett. 2017; 364(23). https://doi.org/10.1093/femsle/fnx226 PMID: 29088370

24. Ortiz AM, Flynn JK, DiNapoli SR, Vujkovic-Cvijin I, Starke CE, Lai SH, et al. Experimental microbial dysbiosis does not promote disease progression in SIV-infected macaques. Nat Med. 2018; 24(9):1313–6. https://doi.org/10.1038/s41598-018-0132-5 PMID: 30061696

25. Manuzak JA, Zevin AS, Cheu R, Richardson B, Modesitt J, Hensley-McBain T, et al. Antibiotic-induced microbiome perturbations are associated with significant alterations to colonic mucosal immunity in rheus macaques. Mucosal Immunol. 2020; 13(3):471–80. https://doi.org/10.1038/s41385-019-0238-1 PMID: 31797911

26. Mosca A, Leclerc M, Hugot JP. Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem? Front Microbiol. 2016; 7:455. https://doi.org/10.3389/fmicb.2016.00455 PMID: 27065999

27. Parker EPK, Praharaj I, John J, Kaliappan SP, Kampmann B, Kang G, et al. Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India. Sci Rep. 2017; 7(1):9168. https://doi.org/10.1038/s41598-017-06862-0 PMID: 28835659

28. Ortiz AM, Brenchley JM. Microbial translocation: translating simian immunodeficiency virus to HIV. Curr Opin HIV AIDS. 2018; 13(1):15–21. https://doi.org/10.1097/COH.0000000000000424 PMID: 29028666

29. Ericsen AJ, Lauck M, Mohns MS, DiNapoli SR, Mutschler JP, Greene JM, et al. Microbial Translocation and Inflammation Occur in Hyperacute Immunodeficiency Virus Infection and Compromise Host Control of Virus Replication. PLoS Pathog. 2016; 12(12):e1006048. https://doi.org/10.1371/journal.ppat.1006048 PMID: 28568659

30. Klase Z, Ortiz A, Deleage C, Mudd JC, Quinones M, Schwartzman E, et al. Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol. 2015; 8(5):1009–20. https://doi.org/10.1038/ml.2014.126 PMID: 25586559

31. Carnathan DG, Wetzel KS, Yu J, Lee ST, Johnson BA, Piaardini M, et al. Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A. 2015; 112(2):518–23. https://doi.org/10.1073/pnas.1407466112 PMID: 25550504

32. Mwatelah R, McKinnon LR, Baxter C, Abdool Karim Q, Abdool Karim SS. Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. J Int AIDS Soc. 2019; 22 Suppl 6(Suppl Suppl 6):e25346. https://doi.org/10.1002/jias.25346 PMID: 31468677

33. Lamb CA, Lamb EIM, Mansfield JC, Sankar KN. Sexually transmitted infections manifesting as proctitis. Frontline Gastroenterology. 2013; 4(1):32. https://doi.org/10.1136/flgastro-2012-100274 PMID: 23914292

34. Hung CC, Ji DD, Sun HY, Lee YT, Hsu SY, Chang SY, et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl Trop Dis. 2008; 2(2):175. https://doi.org/10.1371/journal.pntd.0000175 PMID: 18301730

35. Sui Y, Dzutsev A, Venzon D, Frey B, Thovarai V, Trinchieri G, et al. Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naive macaques. Mucosal Immunol. 2018; 11(4):1219–29. https://doi.org/10.1038/s41385-018-0029-0 PMID: 29858581

36. Tannenbaum J, Bennett BT. Russell and Burch’s 3Rs then and now: the need for clarity in definition and purpose. J Am Assoc Lab Anim Sci. 2015; 54(2):120–32. PMID: 25936957

37. Council NR. Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, DC: The National Academies Press; 2011. 246 p. https://doi.org/10.1258/la.2010.010031 PMID: 21123303

38. USDo A. Animal Welfare Regulations. 2017; 9 CFR §11–§411.
39. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. Journal of virology. 2007; 81(16):8827–32. https://doi.org/10.1128/JVI.00895-07 PMID: 17537848

40. Del Prete GQ, Park H, Fennessey CM, Reid C, Lipkey L, Newman L, et al. Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events. J Virol. 2014; 88(14):8077–90. https://doi.org/10.1128/JVI.01026-14 PMID: 24807714

41. Smedley J, Turkbey B, Bernardo ML, Del Prete GQ, Estes JD, Griffiths GL, et al. Tracking the luminal exposure and lymphatic drainage pathways of intravaginal and intrarectal inocula used in nonhuman primate models of HIV transmission. PLoS One. 2014; 9(3):e92830. https://doi.org/10.1371/journal.pone.0092830 PMID: 24667371

42. Cline AN, Bess JW, Piatak M Jr., Lifson JD. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol. 2005; 34(5-6):303–12. https://doi.org/10.1111/j.1600-0684.2005.00128.x PMID: 16128925

43. Zevin AS, Moats C, May D, Wangari S, Miller C, Ahrens J, et al. Laparoscopic Technique for Serial Collection of Liver and Mesenteric Lymph Nodes in Macaques. J Vis Exp. 2017(123). https://doi.org/10.3791/55617 PMID: 28518089

44. Moats CR, Randall KT, Swanson TM, Crank HB, Armantrout KM, Barber-Axthelm AM, et al. Non-bronchoscopic Bronchoalveolar Lavage as a Refinement for Safely Obtaining High-quality Samples from Macaques. Comp Med. 2020. https://doi.org/10.30802/AALAS-CM-99-990066 PMID: 33153516

45. Ortiz AM, Flynn JK, DiNapoli SR, Sortino O, Vujkovic-Cvijin I, Belkaid Y, et al. Antiretroviral Therapy Administration in Healthy Rhesus Macaques Is Associated with Transient Shifts in Intestinal Bacterial Diversity and Modest Immunological Perturbations. J Virol. 2019; 93(18). https://doi.org/10.1128/JVI.00472-19 PMID: 31270225

46. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2003; 100(21):11515–20. https://doi.org/10.1073/pnas.0802203105 PMID: 18490637